The Global Intravascular Lithotripsy (IVL) Market was valued at USD 954.3 million in 2025 and is estimated to grow at a CAGR of 15.8% to reach USD 4 billion by 2035.
The intravascular lithotripsy (IVL) market is witnessing rapid expansion as demand rises for minimally invasive technologies that improve the treatment of calcified vascular disease. The increasing prevalence of arterial calcification, driven by aging populations and the growing incidence of cardiometabolic disorders, continues to create favorable conditions for market growth. Healthcare providers are increasingly adopting advanced vessel preparation technologies to improve procedural success and optimize patient outcomes during interventional cardiovascular procedures. Continued clinical validation, expanding reimbursement support across major healthcare markets, and ongoing technological advancements are accelerating the transition of IVL from an emerging treatment option to a widely accepted clinical solution. As the global elderly population continues to increase, the number of patients requiring treatment for complex calcified vascular lesions is also expanding. Since vascular calcification becomes more common with advancing age, long-term demand for intravascular lithotripsy technologies is expected to remain structurally strong, supported by sustained clinical need rather than temporary adoption trends. These factors continue to reinforce favorable growth prospects for the global intravascular lithotripsy (IVL) market.
Intravascular lithotripsy catheters and balloons accounted for 82.84% share in 2025, representing USD 790.6 million. This product category maintains its leading position because every IVL procedure requires the use of a new catheter, creating recurring demand for consumable products. In contrast, capital equipment is utilized across multiple procedures over an extended period. The consistent need for single-use devices continues to support strong revenue generation and reinforces the dominance of the catheter and balloon segment throughout the forecast period.
The hospitals segment held 72.2% share in 2025, generating USD 688.5 million. Hospitals remain the primary end users because IVL procedures require specialized cardiovascular treatment facilities, dedicated procedural equipment, and highly trained multidisciplinary clinical teams. Advanced cardiac catheterization laboratories and vascular intervention centers continue to perform many procedures, supported by a comprehensive patient care infrastructure and established reimbursement pathways that encourage continued adoption of IVL technology.
North America Intravascular Lithotripsy (IVL) Market accounted for 41.6% share in 2025, representing USD 397 million. The United States continues to contribute most of the regional demand, supported by favorable reimbursement policies, advanced healthcare infrastructure, growing physician adoption, and increasing utilization of minimally invasive cardiovascular procedures. Continued expansion of clinical applications and supportive healthcare policies is expected to sustain strong market growth across the region throughout the forecast period.
Major companies operating in the global intravascular lithotripsy (IVL) market include Boston Scientific, Abbott, Philips, Shockwave Medical Inc. (Johnson & Johnson), Stryker (Amplitude Vascular Systems, Inc.), Elixir Medical, FastWave Medical, Cagent Vascular, LEPU Medical, and MicroPort. Companies operating in the intravascular lithotripsy (IVL) market are strengthening their competitive position by investing in research and development to enhance device performance, improve procedural efficiency, and expand clinical applications. Manufacturers continue to focus on product innovation, technological advancement, and the development of next-generation treatment solutions that address increasingly complex vascular conditions. Strategic collaborations with healthcare institutions, clinical research organizations, and distribution partners are supporting broader commercial adoption and market expansion. Companies are also increasing investments in regulatory approvals, manufacturing capacity, physician training, and global geographic expansion to improve market access.
This product will be delivered within 2-4 business days.
The intravascular lithotripsy (IVL) market is witnessing rapid expansion as demand rises for minimally invasive technologies that improve the treatment of calcified vascular disease. The increasing prevalence of arterial calcification, driven by aging populations and the growing incidence of cardiometabolic disorders, continues to create favorable conditions for market growth. Healthcare providers are increasingly adopting advanced vessel preparation technologies to improve procedural success and optimize patient outcomes during interventional cardiovascular procedures. Continued clinical validation, expanding reimbursement support across major healthcare markets, and ongoing technological advancements are accelerating the transition of IVL from an emerging treatment option to a widely accepted clinical solution. As the global elderly population continues to increase, the number of patients requiring treatment for complex calcified vascular lesions is also expanding. Since vascular calcification becomes more common with advancing age, long-term demand for intravascular lithotripsy technologies is expected to remain structurally strong, supported by sustained clinical need rather than temporary adoption trends. These factors continue to reinforce favorable growth prospects for the global intravascular lithotripsy (IVL) market.
Intravascular lithotripsy catheters and balloons accounted for 82.84% share in 2025, representing USD 790.6 million. This product category maintains its leading position because every IVL procedure requires the use of a new catheter, creating recurring demand for consumable products. In contrast, capital equipment is utilized across multiple procedures over an extended period. The consistent need for single-use devices continues to support strong revenue generation and reinforces the dominance of the catheter and balloon segment throughout the forecast period.
The hospitals segment held 72.2% share in 2025, generating USD 688.5 million. Hospitals remain the primary end users because IVL procedures require specialized cardiovascular treatment facilities, dedicated procedural equipment, and highly trained multidisciplinary clinical teams. Advanced cardiac catheterization laboratories and vascular intervention centers continue to perform many procedures, supported by a comprehensive patient care infrastructure and established reimbursement pathways that encourage continued adoption of IVL technology.
North America Intravascular Lithotripsy (IVL) Market accounted for 41.6% share in 2025, representing USD 397 million. The United States continues to contribute most of the regional demand, supported by favorable reimbursement policies, advanced healthcare infrastructure, growing physician adoption, and increasing utilization of minimally invasive cardiovascular procedures. Continued expansion of clinical applications and supportive healthcare policies is expected to sustain strong market growth across the region throughout the forecast period.
Major companies operating in the global intravascular lithotripsy (IVL) market include Boston Scientific, Abbott, Philips, Shockwave Medical Inc. (Johnson & Johnson), Stryker (Amplitude Vascular Systems, Inc.), Elixir Medical, FastWave Medical, Cagent Vascular, LEPU Medical, and MicroPort. Companies operating in the intravascular lithotripsy (IVL) market are strengthening their competitive position by investing in research and development to enhance device performance, improve procedural efficiency, and expand clinical applications. Manufacturers continue to focus on product innovation, technological advancement, and the development of next-generation treatment solutions that address increasingly complex vascular conditions. Strategic collaborations with healthcare institutions, clinical research organizations, and distribution partners are supporting broader commercial adoption and market expansion. Companies are also increasing investments in regulatory approvals, manufacturing capacity, physician training, and global geographic expansion to improve market access.
Comprehensive Market Analysis and Forecast
- Industry trends, key growth drivers, challenges, future opportunities, and regulatory landscape
- Competitive landscape with Porter’s Five Forces and PESTEL analysis
- Market size, segmentation, and regional forecasts
- In-depth company profiles, business strategies, financial insights, and SWOT analysis
This product will be delivered within 2-4 business days.
Table of Contents
Chapter 1 Research Methodology
Chapter 2 Executive Summary
Chapter 3 Industry Insights
Chapter 4 Competitive Landscape, 2025
Chapter 5 Market Estimates and Forecast, by Product Type, 2022-2035 ($ Mn)
Chapter 6 Market Estimates and Forecast, by Application, 2022-2035 ($ Mn)
Chapter 7 Market Estimates and Forecast, by Age Group, 2022-2035 ($ Mn)
Chapter 8 Market Estimates and Forecast, by End Use, 2022-2035 ($ Mn)
Chapter 9 Market Estimates and Forecast, by Region, 2022-2035 ($ Mn)
Chapter 10 Company Profiles
Companies Mentioned
- Shockwave Medical Inc (Johnson & Johnson)
- Boston Scientific
- ABBOTT
- ELIXIR
- FASTWAVE MEDICAL
- Stryker (Amplitude Vascular Systems, Inc)
- PHILIPS
- MicroPort
- LEPU MEDICAL
- CAGENT VASCULAR
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 110 |
| Published | July 2026 |
| Forecast Period | 2025 - 2035 |
| Estimated Market Value ( USD | $ 954.3 Million |
| Forecasted Market Value ( USD | $ 4000 Million |
| Compound Annual Growth Rate | 15.8% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
